[go: up one dir, main page]

MX2023013405A - Composicion farmaceutica para prevenir o tratar la fibrosis. - Google Patents

Composicion farmaceutica para prevenir o tratar la fibrosis.

Info

Publication number
MX2023013405A
MX2023013405A MX2023013405A MX2023013405A MX2023013405A MX 2023013405 A MX2023013405 A MX 2023013405A MX 2023013405 A MX2023013405 A MX 2023013405A MX 2023013405 A MX2023013405 A MX 2023013405A MX 2023013405 A MX2023013405 A MX 2023013405A
Authority
MX
Mexico
Prior art keywords
fibrosis
prevention
treatment
pharmaceutical composition
present
Prior art date
Application number
MX2023013405A
Other languages
English (en)
Inventor
Min Jae Cho
Joon Seok Park
Caroline Hee Lee
Min Young Park
Da Jeong Bae
Ji Hyeon Kim
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2023013405A publication Critical patent/MX2023013405A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que puede utilizarse de forma útil para la prevención o el tratamiento de la fibrosis. De acuerdo con la presente invención, hay una característica que el efecto preventivo o terapéutico de la fibrosis se puede mejorar aún más mediante el uso del primer componente y el segundo componente en combinación.
MX2023013405A 2021-05-13 2022-05-02 Composicion farmaceutica para prevenir o tratar la fibrosis. MX2023013405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210062252 2021-05-13
PCT/KR2022/006231 WO2022240036A1 (ko) 2021-05-13 2022-05-02 섬유화증의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2023013405A true MX2023013405A (es) 2023-11-27

Family

ID=84029268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013405A MX2023013405A (es) 2021-05-13 2022-05-02 Composicion farmaceutica para prevenir o tratar la fibrosis.

Country Status (17)

Country Link
US (1) US20240238278A1 (es)
EP (1) EP4338734A4 (es)
JP (1) JP7762224B2 (es)
KR (1) KR20220154616A (es)
CN (1) CN117320718A (es)
AR (2) AR125886A1 (es)
AU (1) AU2022274469B2 (es)
BR (1) BR112023023670A2 (es)
CA (1) CA3213455A1 (es)
CL (1) CL2023003345A1 (es)
CO (1) CO2023015482A2 (es)
EC (1) ECSP23086047A (es)
MX (1) MX2023013405A (es)
PE (1) PE20241171A1 (es)
TW (1) TW202310839A (es)
WO (1) WO2022240036A1 (es)
ZA (1) ZA202310049B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001663A (es) * 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados novedosos de adenina.
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
WO2019183006A1 (en) 2018-03-19 2019-09-26 Liang Gui Bai Methods and compositions for treating idiopathic pulmonary fibrosis
CN112469406B (zh) * 2018-05-31 2024-05-17 财团法人峨山社会福祉财团 硬脂酸用于预防或治疗肺纤维化的用途

Also Published As

Publication number Publication date
PE20241171A1 (es) 2024-05-28
EP4338734A4 (en) 2025-05-07
ZA202310049B (en) 2025-06-25
JP7762224B2 (ja) 2025-10-29
CA3213455A1 (en) 2022-11-17
BR112023023670A2 (pt) 2024-01-30
US20240238278A1 (en) 2024-07-18
ECSP23086047A (es) 2023-12-29
AU2022274469B2 (en) 2025-06-05
AR125886A1 (es) 2023-08-23
AR125885A1 (es) 2023-08-23
WO2022240036A1 (ko) 2022-11-17
CL2023003345A1 (es) 2024-06-07
CO2023015482A2 (es) 2023-11-30
TW202310839A (zh) 2023-03-16
CN117320718A (zh) 2023-12-29
AU2022274469A1 (en) 2023-09-21
JP2024516021A (ja) 2024-04-11
EP4338734A1 (en) 2024-03-20
KR20220154616A (ko) 2022-11-22

Similar Documents

Publication Publication Date Title
PH12023550161A1 (en) Pharmaceutical composition and use thereof
MY209471A (en) Interleukin-2 agents and uses thereof
MY208549A (en) Parp1 inhibitors
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2022001328A (es) Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2021001376A (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2025007173A (es) Formas cristalinas de un inhibidor de her2
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2019078698A3 (ko) 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2021001520A (es) Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
WO2020221916A3 (en) Eutectic composition
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2023006599A (es) Metodos de uso de agentes de interleucina-2.
MX2023013405A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MY203821A (en) Peptides for treatment and prevention of diabetes and associated disorders
WO2020159159A3 (ko) 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물